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Abstract 
Review on RNASET2, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: RNASE6PL, RP11-514O12.3, 
bA514O12.3 
HGNC (Hugo): RNASET2 
Location: 6q27 
Local order: Telomeric to RPS6KA2, centromeric 
to FGFR1OP. 
Note: This gene represents the first human member 
of the Rh/T2/S-glycoprotein family of extracellular 
ribonucleases. It belongs to the recently defined 
class of tumor-antagonizing genes, based on its 
ability to suppress tumor growth in vivo, but not in 
vitro. It is likely involved in the pathogenesis of 
several human neoplasias (both solid and 
haematological) such as ovarian cancer, melanoma 
and non-Hodgkin lymphoma. Mutations in this 
gene have also been recently described in children 
affected by a rare congenital neurological defect. 
Moreover, GWAS studies have recently reported 
the association of gene variants mapping close to 
the RNASET2 gene with susceptibilty to a few 
autoimmune disorders. 
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I-IX: RNASET2 exons; Red boxes: CAS I and CAS II catalytic sites; Dark green boxes: untranslated regions. 
 
 
DNA/RNA 
Description 
The RNASET2 gene has been mapped in the 
peritelomeric region of the long arm of human 
chromosome 6 (6q27), which has been consistently 
reported to be rearreanged in several human 
neoplasias.  
It's coding region is split in 9 exons, spanning 
approximatly 27 kb of genomic DNA. The 
translation initiation codon is located in exon 1 and 
the stop codon in exon 9.  
Exons III and VI encode the two CAS motifs 
(Catalytic Active Sites) responsible for the 
ribonuclease activity of the RNASET2 protein. 
However, the catalytic activity of the RNASET2 
protein is apparently not required for some 
biological functions, as described for other 
members of the T2-Rh-S RNase gene family. 
Transcription 
The RNASET2 gene is transcribed in the telomere-
to-centromere orientation to produce an 
ubiquitously expressed mRNA approximately 1,4 
kb in length. EST clones representing splice 
variants of the same gene have been described. 
Transcription of this gene is rather ubiquitous, with 
highest expression levels being reported in spleen, 
pancreas and leukocytes. 
Pseudogene 
A processed pseudogene showing 85% identity 
with RNASET2 mRNA maps to chromosome 
7p11.2. The expression pattern of this pseudogene 
is not known. 
Protein 
Description 
The aminoacid sequence of RNASET2 depicts a 
typical member of the highly conserved Rh7T2/S 
family of extracellular, acid ribonucleases. The X-
ray structure of the protein was recently reported, 
showing the occurrence of the α+β core fold 
typically observed in other members of the Rh/T2/S 
protein family. The catalytic activity of the protein 
was shown to be significantly inhibited by zinc and 
copper ions. 
Expression 
In normal human tissues, the RNASET2 protein has 
been detected in pancreas, stomach, small intestine, 
colon, salivary glands, liver, thyroid, adrenal 
glands, lymphoid organs, lungs, melanocytes, 
ovarian surface and Fallopian tube epithelium. 
Expression of the RNASET2 protein has also been 
detected in several human ovarian cancer cell lines 
and in some melanoma, prostate, pancreatic and 
breast carcinoma cell lines. 
Localisation 
The full-length RNASET2 protein contains 256 
aminoacids and displays an apparent MW of 36 
kDa in its secreted form. Two 31 and 27 kDa C-
terminal proteolytic products have also been 
observed intracellularly in several human cancer 
cell lines.  
 
The RNASET2 protein contains 256 aminoacids. Gold box: signal peptide for secretion (residues 1-24); Gray box: catalytic fold; 
Red boxes: Conserved Active Sites (CAS I-II); Yellow boxes: putative N-glycosilation sites. 
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The extracellular RNASET2 protein is detected in 
cell culture supernatants as the full lenght 36 kDa 
forms. The intracellular localization pattern of the 
RNASET2 protein suggests a localization in the 
secretory compartments (endoplasmic reticulum 
and Golgi apparatus) but also in lysosomes and 
processing bodies (P-bodies). 
Function 
Biochemical function: RNASET2 is an acid 
ribonuclease with optimal activity at pH 5 and 
preferential cleavage of poly-A and poly-U homo-
polyribonucleotides. 
Biological function: RNASET2 behaves as a tumor 
antagonizing gene in ovarian cancer models, since 
experimental manipulation of this gene's expression 
levels in human ovarian cancer cell lines is 
associated with a significant change in their 
tumorigenic and metastasizing potential in vivo. 
The oncosuppressive role of this protein in ovarian 
cancer models is associated with a marked 
recruitment of cells form the monocyte/macrophage 
lineage within the tumor mass.  
In an experimental model of colorectal cancer, 
recombinant RNASET2 was also found to display a 
marked oncosuppressive activity. Strikingly, in 
both models the ribonuclease catalytic activity was 
apparently dispensable for RNASET2 to play such 
antioncogenic role.  
A role for in vivo tumor suppression for RNASET2 
has also been established in a model of malignant 
melanoma. 
Moreover, the human RNASET2 gene has been 
recently implicated in sperm motility and stress-
induced apoptosis in melanocytes. 
Recent investigations carried out on RNASET2 
orthologs have suggested several additional 
biological roles for this gene family, such as in vivo 
priming of dendritic cells for Th2-helper response, 
inhibition of angiogenesis in vivo, ribosomal RNA 
decay in plants and CNS physiology. 
Homology 
The primary sequenze of RNASET2 shows strong 
homology to the Rh/T2/S family of secreted 
ribonucleases. 
Mutations 
Note 
Epigenetics: The RNASET2 gene has been reported 
to be frequently down-regulated in several human 
ovarian cancer cell lines and primary tumors. The 
underlying molecular mechanism is currently 
unknown. 
Germinal 
A common exon-9 missense C708T germline 
mutation has been described but no evidence for an 
association of this allele with human cancer was 
found. 
A missense mutation (550T>C ; C184R) and a 2,5 
kb deletion spanning exon 2 were found to 
segregate in families affected with cystic 
leukoencephalopathy. 
Somatic 
A few common polymorphisms in exons 1, 8 and 9 
have been described. In general, coding mutations 
are rarely found in tumor samples. 
Implicated in 
Ovarian cancer 
Note 
Loss of expression or downregulation of RNASET2 
occurs in a significant fraction of human ovarian 
cancer cell lines and primary ovarian tumours. 
Moreover, the genomic region (chromosome 6q27) 
where the RNASET2 genes maps has been reported 
to be frequently deleted or otherwise rearranged in 
a high fraction of ovarian cancer samples. However, 
no mutation in the RNASET2 gene have been 
described so far in human ovarian cancer samples. 
Therefore, this gene seems to be involved in tumor 
suppression mainly by means of its downregulation 
at the transcript/protein level in this cancer type. 
When overexpressed by gene transfer experiments 
in human ovarian cancer cell lines displaying a low 
level of endogenous mRNA, RNASET2 strongly 
suppresses the tumorigenic and metastatic potential 
of these cell lines in a murine xenogratf model in 
vivo. The same observation was reported following 
a complementary experiment, i.e. by knocking-
down RNASET2 expression in a poorly aggressive 
ovarian cancer cell line expressing high levels of 
endogenous RNASET2. 
In both in vivo models, RNASET2-mediated tumor 
suppression was associated with a marked 
recruitment of cells from the monocyte/macrophage 
lineage in the tumor mass. Further experiments 
have demonstrated a direct chemotactic role for 
cells from the monocyte/macrophage carried out by 
the RNASET2 protein. Very recently, 
downregulation of RNASET2 expression has been 
associated with resistance to cis-platin and 
carboplatin in ovarian cancer cells and tissues. 
Malignant melanoma 
Note 
Besides ovarian carcinoma, the chromosome region 
6q27 (where the RNASET2 genes maps) has been 
reported to be frequently deleted or rearranged in 
malignant melanoma. Downregulation of 
RNASET2 has also been reported in cell lines 
representing this cancer type. Overexpression of 
RNASET2 in the human melanoma-derived SK- 
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MEL28 cell line was associated with a significant 
suppression of tumor growth in vivo (in a xenograft 
model with immunocompromised mice), but not in 
vitro, supporting the notion of RNASET2 as a 
tumor-antagonizing gene whose oncosuppressive 
action is carried out asimmetrically, i.e. only in the 
context of a complex tissue architecture where a 
significant cross-talk between cancer cells and the 
stromal compartment take place. Moreover, the T2 
RNase protein encoded from the Aspergillus niger 
ortholog gene has been shown to inhibit human 
melanoma cell growth and metastasis in a xenograft 
model. The underlying oncosuppressive mechanism 
in this model was the inhibition of tumor 
angiogenesis by means of competitive inhibition 
with angiogenin. 
Colorectal cancer 
Note 
In an HT29 human colon cancer-derived xenograft 
experimental model, human recombinant 
RNASET2 was shown to greatly suppress tumor 
growth in vivo independent from its catalytic 
activity. Tumor angiogenesis was mainly affected 
by recombinant RNASET2 injection in this cancer 
model. 
Anaplastic large cell lymphoma 
Note 
More recently, screening of a protein microarray 
with sera from anaplastic large cell lymphoma 
(ALCL) patients identified RNASET2 as an ALK-
negative ALCL-associated antigen. 
Cystic leukoencephalopathy 
Disease 
Several loss-of function mutations have been 
reported in probands affected by cystic 
leukoencephalopathy, an autosomal recessive 
disorder whose clinical and radiological phenotype 
is indistinguishable with respect to the pattern of 
brain abnormalities observed in people suffering 
from congenital cytomegalovirus infection. 
Affected people develop several neurologic 
abnormalities in the early post-natal period, 
including psychomotor defects, seizures and 
sensorineural hearing impairment, characterized by 
a diagnostic MRI pattern. 
Cytogenetics 
Six independent mutations in the RNASET2 gene 
have been reported in both familial and sporadic 
cases affected by cystic leukoencephalopathy. All 
mutations are predicted to result in a loss of 
function phenotype. 
Abnormal protein 
The C184R mutant RNASET2 protein expressed 
from the 550T>C allele showed defective 
intracellular trafficking, likely due to impaired 
protein folding or stability. 
Autoimmune disorders 
Disease 
Genome-wide association studies have recently 
implicated the RNASET2 locus in the susceptibility 
for a few autoimmune disorder, such as vitiligo, 
Crohns' disease and Graves' disease. 
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